Haemonetics Corporation (NYSE:HAE) Given Average Rating of “Moderate Buy” by Brokerages

Haemonetics Corporation (NYSE:HAE) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $84.4444.

A number of equities research analysts recently commented on HAE shares. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. Mizuho reduced their price target on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. JPMorgan Chase & Co. raised their price objective on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $90.00 target price on shares of Haemonetics in a report on Friday, November 14th.

Haemonetics Stock Performance

HAE opened at $60.56 on Thursday. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The stock has a market cap of $2.81 billion, a P/E ratio of 16.68, a P/E/G ratio of 1.23 and a beta of 0.28. The stock’s 50 day simple moving average is $72.87 and its 200 day simple moving average is $64.18. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The company had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.Haemonetics’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, equities analysts anticipate that Haemonetics will post 4.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Haemonetics in the first quarter valued at approximately $216,000. United Services Automobile Association purchased a new position in shares of Haemonetics during the first quarter valued at approximately $212,000. Empowered Funds LLC boosted its position in Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.